![Marc F. Pelletier](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marc F. Pelletier
Chief Executive Officer at GARDINER HEALTHCARE ACQUISITIONS CORP.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
James Linton | M | 61 |
Iridia, Inc.
![]() Iridia, Inc. Miscellaneous Commercial ServicesCommercial Services Iridia, Inc. operates as a biotechnology company. It offers research and development services. The company was founded by James P. Linton in 2016 and is headquartered in Carlsbad, CA. | 8 years |
Janelle Anderson | M | 51 |
Gardiner Founder LLC
| 3 years |
Paul R. McGuirk | M | 72 |
Aeromics, Inc.
![]() Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH.
Gardiner Founder LLC
| 15 years |
Frank Sciavolino | M | 83 |
Gardiner Founder LLC
| 3 years |
Dave Jenkins | M | - |
Aeromics, Inc.
![]() Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH.
Gardiner Founder LLC
| 5 years |
Jeffrey P. Draime | M | 57 |
Aeromics, Inc.
![]() Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 7 years |
Paul Predki | M | - |
Iridia, Inc.
![]() Iridia, Inc. Miscellaneous Commercial ServicesCommercial Services Iridia, Inc. operates as a biotechnology company. It offers research and development services. The company was founded by James P. Linton in 2016 and is headquartered in Carlsbad, CA. | 8 years |
Matthew Rossen | M | 47 | 3 years | |
Thomas Ryan | M | 46 | 3 years | |
Peter Longo | M | - |
Aeromics, Inc.
![]() Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH.
Iridia, Inc.
![]() Iridia, Inc. Miscellaneous Commercial ServicesCommercial Services Iridia, Inc. operates as a biotechnology company. It offers research and development services. The company was founded by James P. Linton in 2016 and is headquartered in Carlsbad, CA. | 8 years |
Jay Flatley | M | 71 |
Iridia, Inc.
![]() Iridia, Inc. Miscellaneous Commercial ServicesCommercial Services Iridia, Inc. operates as a biotechnology company. It offers research and development services. The company was founded by James P. Linton in 2016 and is headquartered in Carlsbad, CA. | 7 years |
Thomas Zindrick | M | 65 |
Aeromics, Inc.
![]() Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 6 years |
Mark Day | M | 52 |
Aeromics, Inc.
![]() Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 6 years |
Thomas Hoxie | M | - | - | |
Mark Zhu | M | - | - | |
Peter C. Agre | M | - |
Aeromics, Inc.
![]() Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 5 years |
Anthony Caggiano | M | 54 | - | |
Mohendra Moodley | M | - | - | |
Jack Reynolds | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Walter F. Boron | M | - |
Aeromics, Inc.
![]() Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 20 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Marc F. Pelletier
- Personal Network